Advertisement

Megakaryocytopoiesis in Patients with Myelodysplastic Syndromes

  • M. Podolak-Dawidziak
  • D. Geddesa
  • D. Bowen
Conference paper

Abstract

Myelodysplastic syndrome (MDS) is a progressive preleukaemic condition caused by an abnormality of haemopoietic stem cells [1,10] and characterized by both genetic and functional changes [3,4]. Dysmegakaryocyto-poiesis is a common feature in MDS and results in thrombocytopenia in about 50% of cases [4]. Megakaryocyte colony formation was found to be defective in many MDS patients [5,6]. Futhermore, MDS plasma displayed a low ability to support the clonal growth of normal megakaryocytopoietic progenitors [13]. Although the number of marrow megakaryocytes may be decreased, normal or increased, they are often morphologically abnormal with reduced size (micromegakaryocytes) [2,14,19] and small hypo- or nonlobulated nuclei [13,16]. The degree of dysmegakaryocytopoiesis along with the degree of dysgranulocytopoiesis has been introduced as an additional criterion aiming at better prediction of patients’ survival than that based on the French-American-British Group (FAB) classification alone [1,18].

Keywords

Acute Myeloid Leukemia Myelodysplastic Syndrome Normal Bone Marrow Refractory Anaemia Sideroblastic Anaemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C, The French-American-British (FAB) Co-operative group (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199PubMedGoogle Scholar
  2. 2.
    Bracher C (1974) Atypical megakaryocytes. A reflection of a stem cell disorder. In: Baldini M, Ebbe S (eds) Platelets: production, function, transfusion and storage. Grune and Stratton, New York, pp 94–103Google Scholar
  3. 3.
    Greenberg PL (1983) The smouldering myeloid leukemic status: clinical and biologic feature. Blood 61:1035–1044PubMedGoogle Scholar
  4. 4.
    Jacobs A (1985) Myelodysplastic syndrome: pathogenesis, functional abnormalities, and clinical implications. J Clin Pathol 38:1201–1217PubMedCrossRefGoogle Scholar
  5. 5.
    Juvonen E, Partanen E, Knuutila S, Ruutu T (1986) Megakaryocyte colony formation by bone marrow progenitors in myelodysplastic syndromes. Br J Haematol 63:331–334PubMedCrossRefGoogle Scholar
  6. 6.
    Juvonen E, Partanen E, Knuutila S, Ruutu T (1989) Colony formation by megakaryocyte progenitors in myelodysplastic syndromes. Eur J Haematol 42:389–395PubMedCrossRefGoogle Scholar
  7. 7.
    LeBeau MM, Epstein MD, O’Brien SJ, Nienhuis AW, Yang Y, Clark SC, Rowley JD (1987) The interleukin 3 gene is located on human chromosome 5 and is deleted in myeloid leukemias with a deletion of 5q. Proc Natl Acad Sci USA 84:5913–5917CrossRefGoogle Scholar
  8. 8.
    LeBeau MM, Westbrook CA, Diaz MO, Larson RA, Rowley JD, Gasson JC, Golde DW, Sherr CJ (1986) Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disorders. Science 251:984–987CrossRefGoogle Scholar
  9. 9.
    Levine RF (1980) Isolation and characterization of normal human megakaryocytes. Br J Haematol 45:487–497PubMedCrossRefGoogle Scholar
  10. 10.
    Linman JW, Saarni MJ (1974) The preleukemic syndrome. Semin Hematol 11:93–100PubMedGoogle Scholar
  11. 11.
    Messner HA, Jamal N, Izaguirre C (1982) The growth of large megakaryocyte colonies from human bone marrow. J Cell Physiol 1:45–51CrossRefGoogle Scholar
  12. 12.
    Paris Conference (1971) Standarization in human cytogenetics. Birth Defects 8:1972Google Scholar
  13. 13.
    Podolak-Dawidziak M (1989) Stimulation of CFU-Mk colony growth by normal plasma and plasma from myelodysplastic patients. Leuk Res 13:213–215PubMedCrossRefGoogle Scholar
  14. 14.
    Smith WB, Ablin A, Goodman JR, Brecher G (1973) Atypical megakaryocytes in preleukemic phase of acute myeloid leukemia. Blood 42:535–540PubMedGoogle Scholar
  15. 15.
    Sokal G, Michaux JL, van den Berghe H, Cordier A, Rodhain J, Ferrant A, Mariau M, De Bruyere M, Sonnet J (1975) A new hematologic syndrome with a distinct karyotype: the 5q-chromosome. Blood 46:519–533PubMedGoogle Scholar
  16. 16.
    Tricot G, Vlietinck R, Boogaerts MA, Hendriks B, De Wolf-Peters C, van den Berghe H, Verwilgen RL (1985) Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trophine biopsy and chromosomal analysis. Br J Haematol 60:19–32PubMedCrossRefGoogle Scholar
  17. 17.
    van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G (1974) Distinct haematological disorder with deletion of long arm of no 5 chromosome. Nature 251:437–438PubMedCrossRefGoogle Scholar
  18. 18.
    Varela BL, Chuang C, Woll JE, Bennett JM (1985) Modification in the classification of primary myelodysplastic syndromes: the addition of a scoring system. Hematol Oncol 3:55–63PubMedCrossRefGoogle Scholar
  19. 19.
    Wiesneth M, Pflieger H, Kubanek B, Heimpel H (1980) Micromegakaryocytes in human bone marrow. Acta Haematol 64:65–71PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • M. Podolak-Dawidziak
    • 1
  • D. Geddesa
  • D. Bowen
  1. 1.Department of HaematologyMedical AcademyWrocławPoland

Personalised recommendations